FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387247912> ?p ?o ?g. }

• W4387247912 endingPage "A6451" @default.
• W4387247912 startingPage "A6448" @default.
• W4387247912 abstract "SESSION TITLE: Transplantation Posters 2 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm PURPOSE: Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT) carries high morbidity and mortality but can be difficult to identify in its earliest stages, often resulting in substantial disease progression prior to diagnosis and initiation of therapy. While formal NIH pulmonary function test (PFT) criteria are defined for BOS, these stringent criteria may contribute to delayed diagnosis. Quantitative lung strain measurements from conventional inspiratory/expiratory (biphasic) CT chest scans have been used to diagnose obstructive airway diseases such as asthma but have not been applied to detect BOS after HCT. METHODS: Biphasic chest CT scans of HCT recipients from MD Anderson Cancer Center and Stanford University were analyzed. Patients were categorized as typical BOS by NIH criteria, early BOS (irreversible >= 10% forced expiratory volume in 1 second (FEV1) decline not meeting NIH criteria); atypical BOS with restrictive physiology; transient impairment (>= 10% FEV1 decline resolving within 6 months); and controls with non-pulmonary graft-versus-host-disease (GVHD). Quantitative measures of air trapping, Jacobian Index (degree of lung strain), and Anisotropic Deformation Index (ADI, isotropy of lung strain) were analyzed by Wilcoxon rank sum and by K-means clustering to distinguish between controls, transient impairment, and different forms of BOS. RESULTS: Eighty patients were included: 43 typical BOS, 15 early BOS, 6 atypical BOS, 7 transient impairment, and 9 GVHD controls. Early BOS was distinguished from controls and from transient impairment, respectively, by air trapping (p=0.007); mean Jacobian (p=0.01); and Jacobian standard deviation (SD) (p=0.002). Mean ADI (p=0.002) and ADI SD (p=0.004) distinguished early BOS from transient impairment. K-means clustering was optimized to 4 clusters, with cluster 1 capturing 81% (n=13) of controls and transient impairment and cluster 2 capturing 66% (n=10) of patients with Early BOS. Of patients with typical or atypical BOS, 71% (n=12) were in clusters 3 and 4. Air trapping (28%), Jacobian (1.7), and ADI (0.35) of cluster 2 were intermediate between cluster 1 (air trapping 8.4%, Jacobian 2.3, ADI 0.50) and clusters 3 and 4 (air trapping 66.1% and 45.5%, Jacobian 1.3 and 1.5, ADI 0.25 and 0.23). CONCLUSIONS: Lung strain metrics and machine learning can distinguish early BOS from patients with transient impairment and from patients without lung disease. CLINICAL IMPLICATIONS: Diagnosis of early BOS by quantitative biphasic CT prior to meeting NIH criteria for BOS by PFT can potentially guide treatment decisions. DISCLOSURES: No relevant relationships by Mansour Alkhunaizi No relevant relationships by Amin Alousi No relevant relationships by Lara Bashoura No relevant relationships by Christopher Bertini Consultant relationship with Sanofi-Aventis Please note: Ongoing by Mario Castro, value=Consulting fee University Study Grant relationship with Pulmatrix Please note: ongoing by Mario Castro, value=Grant/Research Support Principal Investigator relationship with Shionogi Please note: Ongoing by Mario Castro, value=Study Funding Author relationship with Elsevier Please note: Ongoing by Mario Castro, value=Royalty Removed 03/31/2023 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with Regeneron Please note: Ongoing by Mario Castro, value=Honoraria Consultant relationship with Genentech Please note: Ongoing by Mario Castro, value=Consulting fee Speaker/Speaker's Bureau relationship with Genentech Please note: Ongoing by Mario Castro, value=Honoraria Speaker/Speaker's Bureau relationship with Teva Please note: Ongoing by Mario Castro, value=Honoraria Consultant relationship with Ongoing Please note: Ongoing by Mario Castro, value=Consulting fee Principal Investigator relationship with GALA Therapeutics Please note: 1-21-2020 to present Added 03/31/2023 by Mario Castro, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with Sanofi-Aventis Please note: Ongoing by Mario Castro, value=Honoraria Principal Investigator relationship with Sanofi-Aventis Please note: Ongoing by Mario Castro, value=Study Funding Speaker/Speaker's Bureau relationship with GSK Please note: Ongoing by Mario Castro, value=Honoraria Principal Investigator relationship with PCORI Please note: Ongoing by Mario Castro, value=Study Funding Removed 03/31/2023 by Mario Castro, source=Web Response Principal Investigator relationship with AstraZeneca Please note: Ongoing by Mario Castro, value=Study Funding Speaker/Speaker's Bureau relationship with AstraZeneca Please note: Ongoing by Mario Castro, value=Honoraria Principal Investigator relationship with Novartis Please note: Ongoing by Mario Castro, value=Study Funding Consultant relationship with Novartis Please note: Ongoing by Mario Castro, value=Consulting fee Principal Investigator relationship with GSK Please note: Ongoing by Mario Castro, value=Study Funding Speaker/Speaker's Bureau relationship with Amgen Please note: ongoing by Mario Castro, value=Honoraria Consultant relationship with Merck Please note: ongoing by Mario Castro, value=Consulting fee Principal Investigator relationship with Theravance Please note: Jan 2023-Present Added 03/31/2023 by Mario Castro, source=Web Response, value=Grant/Research Support Consultant relationship with Arrowhead Pharmaceuticals Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Consulting fee Consultant relationship with Allakos Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Consulting fee Consultant relationship with Aer Therapeutics Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Stockoption, none owned yet Consultant relationship with Pioneering Medicines Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Consulting fee Consultant relationship with OM Phamra Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Consulting fee Removed 03/31/2023 by Mario Castro, source=Web Response Consultant relationship with Om Pharma Please note: Jan 2023-present Added 03/31/2023 by Mario Castro, source=Web Response, value=Consulting fee No disclosure on file for Richard Champlin No relevant relationships by Guang-Shing Cheng No disclosure on file for Keshav Datta No relevant relationships by Burton Dickey financial interest relationship with Imbio, LLC Please note: 2014-Present Added 04/14/2023 by Craig Galbán, source=Web Response, value=Royalty No disclosure on file for Myrna Godoy No relevant relationships by Haiwei Guo No disclosure on file for Maria Hernandez Founder and Share Holder relationship with VIDA Diagnostics Please note: 1994 to present Added 03/31/2023 by Eric Hoffman, source=Web Response, value=Nothing received No disclosure on file for Joe Hsu No disclosure on file for Stephen McEleney Employee relationship with VIDA Please note: 3/2017-present Added 04/03/2023 by Samuel Peterson, source=Web Response, value=Salary Owner/Founder relationship with VIDA Diagnostics, Inc Please note: 1/1/2000-present Added 03/31/2023 by Joseph Reinhardt, source=Web Response, value=Ownership interest Consultant relationship with Auris Health, Inc. Please note: 3/1/2023-present Added 03/31/2023 by Joseph Reinhardt, source=Web Response, value=Consulting fee Consultant relationship with Auris Health, Inc. Please note: 3/1/2020-12/31/2021 Added 03/31/2023 by Joseph Reinhardt, source=Web Response, value=Consulting fee No relevant relationships by Gabriela Rondon No relevant relationships by Husham Sharifi Consultant relationship with Psioxus Therapeutics Please note: 3/1/20-7/1/20 by Ajay Sheshadri, value=Consulting fee Removed 12/05/2022 by Ajay Sheshadri, source=Web Response Consultant relationship with Enanta Pharmaceuticals Please note: 01/01/21-ongoing by Ajay Sheshadri, value=Consulting fee Consultant relationship with Novartis Please note: 10/18/19-10/18/2021 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Mesoblast Please note: 4/22/2020-4/21/2021 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Synthego Corporation Please note: 7/7/2021-7/7/2021 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Bayer Please note: 7/15/2020-7/14/2021 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with ASC Therapeutics Please note: 9/10/2020-9/10/2021 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Magenta Please note: 1/25/2021-1/24/2022 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Cimeio Therapeutics AG Please note: 4/7/2021-4/7/2022 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with NY Blood Center Please note: 4/28/2022-4/27/2023 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Adaptimmune Please note: 10/28/21-10/28/2023 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Navan Please note: 6/7/2021-6/6/2024 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Celaid Therapeutics Please note: 7/1/2022-6/30/2024 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Zelluna Immunotherapy Please note: 9/25/2019-9/25/2024 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with FibroBiologics Please note: 10/15/21-10/15/2024 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee Consultant relationship with Axio Please note: 11/22/19-11/22/2024 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=Consulting fee License agreement relationship with Takeda Please note: Effective 10/28/2019 Added 04/14/2023 by Elizabeth Shpall, source=Web Response, value=License agreement License agreement relationship with Affimed Please note: Effective 12/11/2020 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=License agreement License agreement relationship with Syena Please note: Effective 2/10/2023 Added 04/13/2023 by Elizabeth Shpall, source=Web Response, value=License agreement No relevant relationships by Ihsan Turk No relevant relationships by Gregory Yanik" @default.
• W4387247912 created "2023-10-03" @default.
• W4387247912 creator A5001559244 @default.
• W4387247912 creator A5003544851 @default.
• W4387247912 creator A5008886167 @default.
• W4387247912 creator A5014091530 @default.
• W4387247912 creator A5016928938 @default.
• W4387247912 creator A5029468773 @default.
• W4387247912 creator A5029849168 @default.
• W4387247912 creator A5030094944 @default.
• W4387247912 creator A5034104852 @default.
• W4387247912 creator A5039748322 @default.
• W4387247912 creator A5041197633 @default.
• W4387247912 creator A5046029039 @default.
• W4387247912 creator A5047804569 @default.
• W4387247912 creator A5048913229 @default.
• W4387247912 creator A5049973327 @default.
• W4387247912 creator A5055885795 @default.
• W4387247912 creator A5065158413 @default.
• W4387247912 creator A5066017625 @default.
• W4387247912 creator A5067335100 @default.
• W4387247912 creator A5070937580 @default.
• W4387247912 creator A5084871192 @default.
• W4387247912 creator A5091324299 @default.
• W4387247912 creator A5091846008 @default.
• W4387247912 creator A5052933455 @default.
• W4387247912 date "2023-10-01" @default.
• W4387247912 modified "2023-10-03" @default.
• W4387247912 title "DISTINGUISHING EARLY BRONCHIOLITIS OBLITERANS SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION USING NOVEL LUNG STRAIN METRICS FROM CHEST CT SCANS" @default.
• W4387247912 doi "https://doi.org/10.1016/j.chest.2023.07.4159" @default.
• W4387247912 hasPublicationYear "2023" @default.
• W4387247912 type Work @default.
• W4387247912 citedByCount "0" @default.
• W4387247912 crossrefType "journal-article" @default.
• W4387247912 hasAuthorship W4387247912A5001559244 @default.
• W4387247912 hasAuthorship W4387247912A5003544851 @default.
• W4387247912 hasAuthorship W4387247912A5008886167 @default.
• W4387247912 hasAuthorship W4387247912A5014091530 @default.
• W4387247912 hasAuthorship W4387247912A5016928938 @default.
• W4387247912 hasAuthorship W4387247912A5029468773 @default.
• W4387247912 hasAuthorship W4387247912A5029849168 @default.
• W4387247912 hasAuthorship W4387247912A5030094944 @default.
• W4387247912 hasAuthorship W4387247912A5034104852 @default.
• W4387247912 hasAuthorship W4387247912A5039748322 @default.
• W4387247912 hasAuthorship W4387247912A5041197633 @default.
• W4387247912 hasAuthorship W4387247912A5046029039 @default.
• W4387247912 hasAuthorship W4387247912A5047804569 @default.
• W4387247912 hasAuthorship W4387247912A5048913229 @default.
• W4387247912 hasAuthorship W4387247912A5049973327 @default.
• W4387247912 hasAuthorship W4387247912A5052933455 @default.
• W4387247912 hasAuthorship W4387247912A5055885795 @default.
• W4387247912 hasAuthorship W4387247912A5065158413 @default.
• W4387247912 hasAuthorship W4387247912A5066017625 @default.
• W4387247912 hasAuthorship W4387247912A5067335100 @default.
• W4387247912 hasAuthorship W4387247912A5070937580 @default.
• W4387247912 hasAuthorship W4387247912A5084871192 @default.
• W4387247912 hasAuthorship W4387247912A5091324299 @default.
• W4387247912 hasAuthorship W4387247912A5091846008 @default.
• W4387247912 hasBestOaLocation W43872479121 @default.
• W4387247912 hasConcept C126322002 @default.
• W4387247912 hasConcept C126838900 @default.
• W4387247912 hasConcept C142724271 @default.
• W4387247912 hasConcept C2776739411 @default.
• W4387247912 hasConcept C2777408962 @default.
• W4387247912 hasConcept C2777714996 @default.
• W4387247912 hasConcept C2778821649 @default.
• W4387247912 hasConcept C2781448352 @default.
• W4387247912 hasConcept C2911091166 @default.
• W4387247912 hasConcept C534529494 @default.
• W4387247912 hasConcept C71924100 @default.
• W4387247912 hasConceptScore W4387247912C126322002 @default.
• W4387247912 hasConceptScore W4387247912C126838900 @default.
• W4387247912 hasConceptScore W4387247912C142724271 @default.
• W4387247912 hasConceptScore W4387247912C2776739411 @default.
• W4387247912 hasConceptScore W4387247912C2777408962 @default.
• W4387247912 hasConceptScore W4387247912C2777714996 @default.
• W4387247912 hasConceptScore W4387247912C2778821649 @default.
• W4387247912 hasConceptScore W4387247912C2781448352 @default.
• W4387247912 hasConceptScore W4387247912C2911091166 @default.
• W4387247912 hasConceptScore W4387247912C534529494 @default.
• W4387247912 hasConceptScore W4387247912C71924100 @default.
• W4387247912 hasIssue "4" @default.
• W4387247912 hasLocation W43872479121 @default.
• W4387247912 hasOpenAccess W4387247912 @default.
• W4387247912 hasPrimaryLocation W43872479121 @default.
• W4387247912 hasRelatedWork W1896091522 @default.
• W4387247912 hasRelatedWork W1966155747 @default.
• W4387247912 hasRelatedWork W1966396484 @default.
• W4387247912 hasRelatedWork W1977300388 @default.
• W4387247912 hasRelatedWork W1993492048 @default.
• W4387247912 hasRelatedWork W2018523674 @default.
• W4387247912 hasRelatedWork W2059454317 @default.
• W4387247912 hasRelatedWork W2156675376 @default.
• W4387247912 hasRelatedWork W2404853076 @default.
• W4387247912 hasRelatedWork W4250083931 @default.
• W4387247912 hasVolume "164" @default.
• W4387247912 isParatext "false" @default.
• W4387247912 isRetracted "false" @default.

• next